A review of the LARIAT device: insights from the cumulative clinical experience

• Published in: SpringerPlus Vol. 4; no. 1; p. 522
• Main Authors: Srivastava, Mukta C., See, Vincent Y., Dawood, Murtaza Y., Price, Matthew J.
• Format: Journal Article Book Review
• Language: English
• Published: Cham Springer International Publishing 17-09-2015; Springer Nature B.V
• Subjects: Humanities and Social Sciences; Medicine; multidisciplinary; Review; Science; Science (multidisciplinary); Epicardial ligation; Percutaneous left atrial appendage closure devices; Embolic stroke; Atrial fibrillation
• ISSN: 2193-1801; 2193-1801
• DOI: 10.1186/s40064-015-1289-8

Atrial fibrillation (AF) is the most common arrhythmic disorder world-wide, accounting for 15 % of all strokes. Management of stroke risk in AF is complicated by intolerance of anti-coagulation (AC) therapy and difficulty maintaining therapeutic range in patients treated with warfarin. The left atrial appendage (LAA) is a source of thrombus in AFrelated thrombo-embolic events and surgical LAA exclusion (LAAO) is commonly performed during cardiac surgery in AF patients. Surgical approaches are limited by a high incidence of incomplete closure with a potential for consequent thrombo-embolic events as well as the morbidity of an open-heart procedure. More recently, percutaneous approaches to LAAO have been developed. The LARIAT device is an epicardial LAA exclusion system that enables percutaneous suture ligation of the LAA via combined, pericardial and trans-septal access. The device has 510k Federal Drug Administration (FDA) clearance for soft-tissue ligation and has been studied in canine models in pre-clinical studies as well as published series of clinical experience with LARIAT LAAO. The history, patient selection, procedural technique and complications of LARIAT LAAO are reviewed here. Additionally, insights and procedural improvements that have been elucidated from clinical series and outcomes from the collective experience are discussed. The LARIAT’s epicardial approach to LAA ligation is unique compared with other percutaneous LAA exclusion devices, however more data regarding device safety and efficacy is needed for the LARIAT to emerge as an established therapy for stroke prevention in AF.